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Abstract
Lymphocytes are a key component of the immune system and their differentiation and function are directly influenced by
cancer. We examined peripheral blood lymphocyte (PBL) gene expression as a biomarker of illness and treatment effect
using the Affymetrix Human Gene ST1 platform in patients with metastatic renal cell carcinoma (mRCC) who received
combined treatment with IL-2, interferon-?-2a and dendritic cell vaccine. We examined gene expression, cytokine levels in
patient serum and lymphocyte subsets as determined by flow cytometry (FCM). Pre-treatment PBLs from patients with
mRCC exhibit a gene expression profile and serum cytokine profile consistent with inflammation and proliferation not found
in healthy donors (HD). PBL gene expression from patients with mRCC showed increased mRNA of genes involved with T-
cell and TREG-cell activation pathways, which was also reflected in lymphocyte subset distribution. Overall, PBL gene
expression post-treatment (POST) was not significantly different than pre-treatment (PRE). Nevertheless, treatment related
changes in gene expression (post-treatment minus pre-treatment) revealed an increased expression of T-cell and B-cell
receptor signaling pathways in responding (R) patients compared to non-responding (NR) patients. In addition, we
observed down-regulation of TREG-cell pathways post-treatment in R vs. NR patients. While exploratory in nature, this study
supports the hypothesis that enhanced inflammatory cytotoxic pathways coupled with blunting of the regulatory pathways
is necessary for effective anti-cancer activity associated with immune therapy. This type of analysis can potentially identify
additional immune therapeutic targets in patients with mRCC.
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Introduction
Renal cell carcinoma (RCC) accounts for approximately 5% of
all malignancies. [1,2] Currently available treatment options for
patients with metastatic disease (mRCC) rarely result in a cure.
Although IL-2 based immunotherapy carries significant acute
toxicity, it is the only treatment to date, that results in durable
complete remissions in about 5% of patients. [3–5] Due to the lack
in understanding of both the complex interaction between the
tumor and the host immune system, and the host of factors that
lead to response to immune therapy, it cannot be as yet predicted
who will benefit from IL-2. While initial studies suggested that
tumors expressing high levels of carbonic anhydrase IX (CAIX), a
hypoxic inducible factor, respond better to IL-2 therapy, a
prospective trial failed to confirm this. [6,7].
Gene expression profiling, an important tool to study complex
biological processes, can map involved genes to known pathways
and thus is useful for hypothesis generation. [8,9] In this study we
used microarray technology to highlight differences in gene
expression of the peripheral blood lymphocyte population (PBL)
in mRCC patients compared to healthy controls. We further
evaluated PBL gene expression patterns for pre and post-therapy
from patients treated with a combined immunotherapy regimen
which resulted in a 50% clinical response rate. Since the PBL
includes most of the cellular subsets thought to participate in the
immune surveillance of cancer (T cells, B cells, and NK cells), this
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analysis can provide a comprehensive snapshot of immune status
using a simple tool and potentially complement measurements
made on tumor infiltrating lymphocytes. [8,10–12].
Materials and Methods
Treatment of Patients and Isolation of PBLs and Serum
Protocol D0238 (Phase II Clinical Trial with IL-2, IRN-a2a and
autologous dendritic cell (DC) tumor vaccination) and Leukaphe-
resis Protocol D9726 were approved by the Dartmouth College’s
Committee for the Protection of Human Subjects (CPHS).
As previously described, 18 informed and consented patients
(mean age 61 years, 5 females, 13 males) with advanced mRCC
were treated within a phase II clinical trial with IL-2, IFN-a2a and
autologous dendritic cell (DC) tumor vaccination. [13] All
procedures are conducted according to the principles expressed
in the Declaration of Helsinki. Briefly, peripheral blood monocytes
were cultured ex vivo into mature autologous tumor lysate loaded
DCs and frozen for future vaccines. Treatment consisted of 5
cycles of one intranodal vaccination of DCs, 5-days of continuous
intravenous infusion of IL-2 (18MiU/m2) and 3 subcutaneous
injections of IFN-a2a (6MiU) every other day. PBLs for
microarray analysis and flow cytometry, and serum samples for
cytokine analysis were obtained pre-treatment and post-treatment
(3 weeks after the 2nd of 5 vaccination cycles and 2 weeks after
completion of the 2nd cycle of IL-2 and IFN-a2a therapy). PBLs
were isolated from pheresis product by elutriation fractionation.
Since age is known to affect the status of the immune system, we
identified 9 older healthy donors who signed our CPHS approved
consent and underwent leukapheresis. [14,15].
PBL mRNA Extraction and Gene Microarrays
Total RNA was isolated from PBLs using RNAeasy kit
(Quiagen, Valencia, CA) according to the manufacturer’s instruc-
tion. Hybridizations were performed according to Affymetrix
guidelines (Affymetrix, Santa Clara, CA) at the Dartmouth
College Microarray Shared Resource. Biotin-labeled cDNA was
generated from 5.5 mg of total RNA and hybridized to the
GeneChipH Human Gene 1.0 ST Array. The stained array was
scanned at 532 nm using an Affymetrix GeneChip Scanner 3000.
Microarray analysis and description was carried out according
to Minimum Information About a Microarray Experiment
(MIAME) guidelines. The dataset has been deposited in NCBI’s
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc =GSE34465) and is accessible through GEO
Series accession number GSE34465.
Flow Cytometry of Lymphocyte Subpopulations
Lymphocyte subpopulations were characterized by standard
five-color flow cytometry and analyzed with FlowJo software. [16]
Intracellular staining for IL-4 (R&D) and IFNc (BD Pharmingen)
was done following cell fixation and permeabilization and intra-
nuclear staining for FoxP3 (BioLegend FoxP3 kit) was done as
previously described. [13].
Luminex Assay for 27 Serum Cytokines
LuminexH fluorescent bead technology was used to measure
serum levels for 27 cytokines [IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic fibroblast
growth factor, Eotaxin, granulocyte colony-stimulating factor,
granulocyte macrophage colony-stimulating factor, IFN-c, IP-10,
MCP-1 (MCAF), MIP-1a, MIP-1 b, platelet-derived growth factor
(PDGF), RANTES, tumor necrosis factor-a, vascular endothelial
growth factor]. Serum of 7 patients PRE (3 R, 4 NR) and 8
patients POST (4 R, 4 NR), as well as 5 healthy controls were
analyzed according to manufacturer’s protocol. [13] Due to
limitations in patients material serum could not be analyzed for all
patients.
Response Criteria
To determine how gene expression, lymphocyte subsets and
serum cytokine levels related to clinical outcome, we categorized
patients according to clinical response using RECIST 1.0 criteria.
[17] Overall objective clinical response rate for the total of 18
patients treated was 50% with three complete responses. The 17
pre-treatment patients included in our analysis were 9 R and 8
NR. Post-treatment, 13 patients (8 R, 5 NR) could be included in
our microarray analysis, due to limited availability of PBLs for this
time point.
Microarray Data Analysis & Statistics
Chip-quality was controlled with AffymetrixH expression
consoleTM. As the computational basis, open source R software
package (http://www.r-project.org) and tools from Bioconductor
(www.bioconductor.org) were used. Probe level data of raw
Affymetrix cell intensity (CEL) files were normalized and
summarized using robust multichip average (RMA). When
discussing gene expression, we refer to summarized probe set
expression values. Our analysis follows practices suggested by The
MicroArray Quality Control (MAQC) project augmented with a
novel exploratory use of k-means analysis in the context of
pathway analysis. [18–20] The MAQC recommends selection of
genes of interest based on a fold change cutoff combined with a
non-stringent p-value. We identified genes as differentially
expressed if they achieved: A) a fold difference between conditions
of 1.4 or greater and B) a t-test significance ,0.05 assuming
unequal variance. For comparison of serum cytokine levels as well
as surface marker expression, Student t-Test or Whitney rank sum
test was used to test for differences between groups. P,0.05 was
considered significant and values were expressed as mean 6 StD.
Biological Interpretation
Pathway analysis. Canonical pathways were generated
through the use of Ingenuity Pathway Analysis (IPA, Ingenuity
SystemsH, http://www.ingenuity.com) and Kyoto Encyclopedia of
genes and genome (KEGG) database. IPA provides computational
algorithms to identify and generate significant biological networks
and pathways that are particularly enriched with identified genes
of interest. The significance of the association between the data set
and the canonical pathway is measured by: 1) a ratio of the
number of molecules from the data set that map to the pathway
divided by the total number of molecules that map to the
canonical pathway. 2) Fisher’s exact test for p-value calculation,
determining the probability that the association between the genes
in the dataset and the canonical pathway is explained by chance
alone. We also performed independent Gene set enrichment
analysis (GSEA) for up-regulated and down-regulated gene lists to
test for enrichment of involved pathways. [21] KEGG and IPA
derive their data from published work. Since there is a recognized
lack of consistency between these two databases, [22] we focused
on pathways that are enriched in both platforms or in one
platform as well as in GSEA.
Clustering Analysis
Nonhierarchical unsupervised cluster analysis: K-means analysis
was used to identify candidate paths as follows: we identified 190
KEGG paths with at least 5 genes that mapped to our microarray
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probes. We used k-means as implemented in R to identify two
distinct sample clusters based on the gene expression values in
each pathway. Finally, we then used p values from Fisher’s exact
test to assess the strength of the association between k-means
clusters.
In addition, we used Manhattan distance to perform hierarchi-
cal unsupervised clustering. The degree of similarity using the
Manhattan distance tends to become larger for pairs of vector data
that are less similar, and outlying data are slightly emphasized.
[23].
Confirmation of Selected Genes with Quantitative Real
Time PCR
After reverse transcription of 1 ug total RNA using Quiagen
reverse transcription kit (Quiagen, Valencia, CA), quantitative real
time PCR was performed using the iCycler iQ Real-Time
detection System (Bio-Rad Laboratories, http://www.bio-rad.
com) and specific primer assays from Quiagen (Quiagen, Valencia,
CA, Table S1). GAPDH was used as house-keeping gene. PCR
analysis confirmed the gene chip expression data (Table S2).
Analysis of Gene Expression Data, PBL Subsets and
Serum Cytokine Levels
Analysis of gene expression (GE), serum cytokine levels (SCL)
and lymphocyte subsets (LS) was performed for disease effects by
comparing results for HD vs. mRCC patients PRE (GE: n= 9 vs.
17, SCL: n= 5 vs. 7, LS: n= 9 vs. 17). For analysis of treatment
effects mRCC patients PRE vs. mRCC patients POST results
were compared (GE: n= 17 vs. 13, SCL: n= 7 vs. 8, LS: n= 17 vs.
17). We also examined differentially expressed genes for R vs. NR
PRE and POST as well as R PRE vs. R POST and NR PRE vs.
NR POST (R PRE: n=GE:9, SCL:3, LS:8, R POST: n=GE:8,
SCL:4, LS:8, NR PRE: n=GE:8, SCL:4, LS: 9, NR POST:
n=GE:5, SCL:4, LS:9).
Results
Difference in Gene Expression, Serum Cytokine Level and
Lymphocyte Subsets of mRCC Patients vs. Healthy
Controls
The gene expression profiles of PBLs from patients PRE and
POST and from healthy donors (control) were all compared by
unsupervised hierarchical clustering using Manhattan distance
after mean centering for definition of hierarchy. This cluster
analysis revealed that patients with mRCC, both PRE and POST,
have a gene expression profile signature that is clearly distinct from
HD (Figure 1A). To identify key biological pathways altered in
mRCC patients, we used IPA. This platform identified pathways
reflecting an overall activation of the immune system (Figure 1B).
The most enriched pathway in PBLs was the polyamine regulation
in colon cancer pathway (p = 261027), which revealed the
transcription factor Myc as over-expressed in lymphocytes from
mRCC patients suggesting an overall increase in gene transcrip-
tion, as Myc may regulate up to 15% of all genes. [24].
Additional identified key pathways are involved in regulating
effector T cell activation. Supervised hierarchical clustering for T-
cell and B-cell receptor associated genes for all arrays revealed a
clear clustering of patients from healthy controls (Figure S1). On
closer inspection, the pathways that are up-regulated in association
with mRCC reflect a gene expression profile of enhanced
transcriptional activity and overall activation of innate and
adaptive immune pathways. The overall up-regulation of genes
in the cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
signaling pathway (p= 561025 Figure 1B) suggests active inhib-
itory pathways in CD4 effector T cells or a potential TREG cell
involvement in mRCC patients. Among the top 5 most
significantly affected canonical pathways, we noted an increased
expression of genes associated with the cdc42 signaling pathway
but an overall decrease in genes associated with the eicosanoid
signaling pathway (Figure 1B) for mRCC PBLs. In addition,
GSEA showed activation of FoxP3 targets, as well as activation of
T-cell receptor signaling and TGFß-signaling for patients when
compared to HD (Figure 2).
A pattern of immune system activation in mRCC patients is
further supported by results from our serum-cytokine analysis of
27 immune relevant cytokines and chemokines. In serum from
healthy donors (n = 5), only 4 cytokines had detectable levels in
every healthy control (IL-6, IFN-c, PDGF and RANTES). 15
cytokines had higher levels in patients PRE serum compared to
serum from healthy controls (IL-1ra, IL-4, IL-6, IL-7, IL-8, IL-12,
IL-13, G-CSF, IFN-g, IP-10, MIP-1a, MIP-1b, PDGF, RANTES,
VEGF). 10 of these contrasts reached statistical significance
(Table 1). Up-regulation of PDGF-signaling was further supported
by the IPA results (Figure 1B). The significantly up-regulated genes
are important in T-cell, as well as B-cell development, activation
and proliferation (IL-1ra, IL-4, IL-6, IL-7 and RANTES),
angiogenesis (PDGF, VEGF), inflammation (MIP-1b, VEGF) or
are stimulated by IFN gamma (IP-10). Th1 as well as Th2 specific
cytokines were up-regulated, reflecting a state of immune
activation.
Lymphocyte subset analysis by flow cytometry showed that
mRCC patients had an up-regulation of CD4+ T-cells
(47.6615.6% HD vs. 61.7612.7% mRCC, p,0.05) and a
simultaneous down-regulation of cytotoxic CD8+ T-cells
(48.3614.7% HD vs. 35.8613.0% mRCC, p,0.05). Furthermore
regulatory T(TREG) cells, defined as CD25
+FoxP3+ T cells
(CD3+CD4+) were significantly up-regulated in mRCC patients
(1.360.5% vs.2.961.0%, p,0.001). [13].
The properties of circulating T regulatory cells of the same
patients and healthy volunteers were evaluated separately com-
bining phenotype examination, DNA methylation analysis and
global transcriptome analysis. [25] Data from all three types of
analysis, microarray analysis, serum cytokine levels and cell subsets
based on FCM show patterns which are indicative of immune
activation including more inhibition and suppression of the
immune system in mRCC patients compared to healthy donors.
Treatment-related Effects on Gene Expression
To explore treatment-related effects on gene expression in
mRCC patients, in addition to unsupervised hierarchical cluster-
ing (Figure 1A), a supervised cluster analysis was performed that
revealed broad similarities in the gene expression profiles of
patients’ pre and post-treatment PBLs (Figure S2). We could not
discern a specific set of genes or key pathways that could
discriminate a treatment effect.
Gene Expression Profiles and Clinical Outcome
We investigated the data set for a gene expression profile that
could predict response to immune therapy by comparing the gene
expression of responders and non-responders pre-treatment PBL.
Supervised analysis of patient PRE data revealed broad similarities
in both groups of patients, as responders and non-responders
clustered together (Figure S3A). Furthermore, there were no clear
differences in the gene expression profile of patients POST PBL
that could be correlated with clinical outcome (Figure S3B).
To interrogate the data further we analyzed lists of differentially
expressed genes between R POST vs. R PRE (n= 8 vs. 9) as well
Gene Expression in PBLs of RCC Patients
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as NR POST vs. NR PRE (n= 5 vs. 8) with IPA. This analysis
revealed that T-cell (Figure 3A) and B-cell (Figure 3B) receptor
pathways were differentially regulated in responders and non-
responders upon treatment. Responding patients, as a group,
exhibit up-regulation of genes enriched for these pathways
(Figure 3 A and B, right) while non-responding patients seemed
to down-regulate those genes (Figure 3 A and B, left). This is again
complemented by flow cytometry results, where the subset of TH2
T cells (IL4+ % of CD4+) significantly increases with treatment
(PRE mRCC: 4.263.0% vs. POST mRCC: 8.967.1%, p,0.05)
and this effect is due to the subset of responding patients (PRE R:
4.863.7% vs. POST R: 12.068.1%, p,0.05) not the non-
responding patients (PRE NR: 3.662.2% vs. POST NR:
4.861.5%, ns).
Furthermore, genes associated with the CD28 and NFAT
signaling pathways were differentially expressed in responding and
non-responding subjects in POST vs. PRE comparison. The
CD28 co-stimulatory, nuclear factor of activated T cell (NFAT)
and HIFa pathways were relatively up-regulated in responding
subjects upon immunotherapy (Figure 4A–4C). Another key
pathway (IPA) differentially regulated in R vs. NR PBL was the
Flt3 signaling pathway (fms-like tyrosine kinase receptor-3) where
genes were overall down-regulated in non-responding patients but
up-regulated in responding patients (Figure 4D) as a result of
treatment. Unsupervised clustering of genes from this pathway
grouped POST responders and POST non-responders in 2
distinct groups (Figure 4D, bottom, left), suggesting that stimulat-
ing this pathway may be required to achieve a good clinical
response.
Our analysis of possible response related genes also revealed
that our immunotherapy regimen altered the CTLA-4 status of
responding patients. Whereas patients PRE compared to healthy
controls showed an activation of CTLA-4 signaling, this activation
appeared to be reversed in responding patients following
treatment. CTLA-4 pathway related genes in responders POST
PBL are down-regulated compared to POST PBL of non-
responding patients (Figure S4).
Subset analysis by FCM and cytokine multiplex results also
revealed differences between responding and non-responding
patient samples. The proportion of TREG cells in the PBL, a key
inhibitory cell subset, increases as a result of treatment for the NR
patients compared to the R patients. (R PRE: 1.561.0% vs. R
POST: 2.761.0%, NR PRE: 2.360.8% vs. NR POST:
7.062.8%). [13] Cytokine multiplex results showed an overall
treatment related increase in serum levels of anti-angiogenic factor
IP-10 (PRE 126671 pg/ml vs. POST 5216244 pg/ml, p = 0.002,
(Figure S5). Responding patients had higher levels of IP-10 in PRE
serum than non-responding patients (R 139641 pg/ml vs. NR
82644 pg/ml, p = 0.08). Baseline IP-10 levels have been shown to
correlate with clinical outcome in renal cell carcinoma and
hepatocellular carcinoma. [16,26] IP10 was the only serum
cytokine level measured which differed based on treatment or
response.
Discussion
Global immune dysfunction develops in many patients with
advanced tumor burden and alterations of the immune response
may compromise immunotherapeutic approaches. [27–30] To
investigate this further, we interrogated the gene expression profile
of immune cells in the peripheral blood compartment. In this
study, to corroborate microarray data, we measured the mRNA of
selected genes independently by quantitative real-time PCR. We
Figure 1. Comparison of gene expression of PBLs of mRCC patients and healthy controls following normalization of microarray
expression data. A: Microarray Data: The gene-expression profiles of PBLs from all patients (pre- and post-treatment) and from healthy donors
(control) were compared by unsupervised hierarchical clustering using Manhattan distance after mean centering for definition of hierarchy. Shown is
a correlative or adjacency matrix. A gene expression profile for each chip is calculated and compared with those of all other chips. The chips with
similar gene expression profile cluster together. Red denotes a large distance between gene expression of arrays; dark blue means no distance
(diagonal line). The largest distance can be detected for the comparison Control1 versus mRCC patient 16 Post. B: Ingenuity Pathway Analysis (IPA): A
list of highly altered pathways after comparing gene expression between healthy controls and patients pre-treatment. Percentage of genes (of all
known involved genes) altered in our dataset is shown on the top axis. Orange bars indicate up-regulation of genes and blue bars indicate down-
regulation of genes. The bottom axis shows the log p-value that indicates how significantly the identified genes are associated to the pathway. IPA
identified pathways reflecting an overall activation of the immune system as well as an alteration of T- and B-cell signaling pathways.
doi:10.1371/journal.pone.0050221.g001
Figure 2. Comparison of gene expression of PBLs of mRCC
patients and healthy controls following normalization of
microarray expression data. Gene Set Enrichment Analysis
(GSEA) was performed for 17 mRCC patients PRE (yellow
background,#10–26) vs. 9 healthy controls (grey background,
#1–9). GSEA uses a Kolmogorov Smirnov statistic to explore unique
gene signature of small groups of genes within a data set. Shown are
representative pathways that were up-regulated in the mRCC samples
(p,0.05).
doi:10.1371/journal.pone.0050221.g002
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also quantified serum cytokine levels by enzyme-linked immuno-
sorbent assay (ELISA) based multiplex analysis and determined
the proportions of key lymphocyte cell subsets by flow cytometry
analysis.
Our data show that the gene expression profile of PBLs in
patients with mRCC compared to healthy volunteers reflects an
inflammatory process with opposing signals: an increased expres-
sion of genes associated with T-cell activating pathways such as T-
and B-cell receptor signaling, as well as heightened expression of
genes involved in regulatory pathways such as CTLA4. This is
reflected in altered lymphocyte subsets in mRCC patients as well
as in increased serum cytokine levels. The overall gene expression
of patients post-treatment vs. patients pre-treatment did not reveal
relevant changes. This may reflect that the effects of mRCC on
immune status include pro-inflammatory signals as well as signals
that can inhibit anti-tumor responses. Our findings did not reveal
any clear predictive value in the gene expression profile of patient
pre-treatment PBL that could be correlated with outcome.
However, analysis of POST minus PRE changes in gene
expression in responders and non-responders demonstrated
differential regulation of regulatory and inhibitory pathways in
these two cohorts of patients and is supportive of the importance of
therapeutic targeting of such pathways. These findings underscore
the potential utility of gene expression signatures associated with
disease-specific immune pathways to identify immune therapeutic
targets in patients with cancer.
Twine et al. have reported disease-associated differences in the
gene expression profile of peripheral blood mononuclear cells
(PBMCs) from RCC patients compared to PBMCs of healthy
volunteers. [9] Similar to our observations they report an
induction of inflammatory-related genes. Correlation of fold
changes of the 132 m-RCC related genes identified in the Twine
dataset to fold changes for our data set revealed no similarities
(Figure S6), although clustering analysis applying the Twine gene
set, clearly discriminated our patients and healthy controls. The
differences in gene expression may be related to the source of cells
used for the two studies, PBMCs in the Twine study as compared
to PBLs used in our study, and may also relate to the pool of
healthy donors used for comparison in each study. [31] A meta-
analysis of 47 studies emphasizes the global predicting role of
systemic inflammatory response for relapse free survival in RCC.
[32].
In our study, further pathway analyses with Ingenuity revealed
an up-regulation of genes belonging to B-cell receptor and T-cell
receptor signaling pathways in mRCC patients compared to
healthy donors. The detected changes of genes in these pathways
are supported by the documented importance of T-cell function,
cell number, and specific T-cell functional pathways in the mRCC
literature. [27,33,34].
While we observed increased levels of cytokines in the serum of
patients with mRCC vs. healthy donors, [13] we were not able to
demonstrate a corresponding increased expression in peripheral
blood lymphocyte cytokine genes (data not shown). This suggests
that the cytokine production may originate from another source
(e.g. tumor infiltrating lymphocytes, RCC, endothelial cells,
macrophages) or that the clearance from circulation of these
cytokines is in some way diminished in patients with mRCC. The
increase of cytokine levels could as well be due to an increase
release of cytokines from internal compartments. [35].
We found treatment related up-regulation of 15 cytokines/
chemokines including interferon IFN-c inducible protein 10 (IP-
10), Interferon gamma (IFN-c), macrophage inflammatory protein
(MIP)-1b and regulated upon activation normal T expressed and
secreted (RANTES) in mRCC patient serum. Expression of these
four cytokines within hepatocellular carcinoma correlated with a
favorable prognosis. [26] This study of mRNA expression in
Table 1. Serum cytokine (27 plex) assay results.
Healthy control n =5 Patients pre treatment n=7
Limit of detection
[pg/mL] Mean [pg/mL] ± SD Mean [pg/mL] ± SD t-test p value
IL-1ra 1.4 13.2618.1 (in 2/5) 129.9638.5 0.111
IL-4 0.5 ,0.5 2.160.7 0.004*
IL-6 1.1 3.660.5 13.169.4 0.072
IL-7 0.5 3.663.9 (in2/5) 10.362.7 0.009*
IL-8 0.5 3.4 (in 1/5) 7.765.8 0.166
IL-12 0.5 ,0.5 2.661.9 0.326
IL-13 2.1 ,2.1 9.366.6 0.296
G-CSF 1.1 4.466.1 (in 2/5) 17.167.2 0.017*
IFN-c 1.0 7.063.1 16.664.0 0.025*
IP-10 6.5 8.8 (in 1/5) 106.9649.9 0.002*
MIP-1a 2.4 ,2.4 3.461.4 0.027*
MIP-1b 1.1 6.0 (in 1/5) 83.4624.6 ,0.001*
PDGF bb 1.0 1100.86764.3 6205.662242.2 ,0.001*
RANTES 1.2 2624.86772.9 5594.16908.3 ,0.001*
VEGF 0.5 7.867.6 (in 3/5) 123.4695.9 0.010*
*p,0.05.
Ten cytokines showed significant up-regulation in patients vs. healthy controls; 5 additional cytokines showed a clear increase in mRCC patients, but due to low sample
size and high standard deviations these contrasts did not reach significance. IL-1b, IL-2, IL-5, IL-9, IL-10, IL-15 and IL-17 had detectable values in very few of the 16 tested
samples and were thus excluded from the analysis and table.
doi:10.1371/journal.pone.0050221.t001
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Figure 3. Separate comparison of gene expression post-treatment versus gene expression pre-treatment for responding and non-
responding patients. Ingenuity pathway analysis suggests differences in regulation of T-cell (Figure 3A) and B-cell (Figure 3B)
receptor signaling. Most of the molecules in the B-cell as well as in the T-cell receptor pathway are down-regulated for non-responding patients
upon immunotherapy (POST ,PRE), whereas gene expression of the same molecules is up-regulated for responding patients (POST .PRE). Red: up-
regulation, Green: down-regulation.
doi:10.1371/journal.pone.0050221.g003
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hepatocellular carcinoma suggested that the anti-tumorigenic
activities of these cytokines may result from the recruitment of
tumor infiltrating lymphocytes to amplify the anti-tumor immune
responses. Another study of RCC tumor tissue revealed that Th1
cytokine expression, e.g. Interferon gamma induced cytokines like
IP-10, to be a favorable prognostic factor of survival after surgery.
[16].
There were no detectable global differences in the gene
expression profile of patients before (PRE) or after therapy
(POST) that could be correlated to response. The absence of
detectable treatment-related effects may be due to the timing of
the POST sample used for gene expression profile analysis. It is
possible that differences in gene expression are no longer
detectable at 2 weeks following treatment, when POST PBLs
were collected. Overall, these data suggest there are no lasting
effects in the PBL gene expression profile of patients after
treatment with DC-vaccine, IL-2 and IFN therapy.
However, further analyses revealed pathway-specific differences
in responders and non-responders. We observed an increase in
gene expression pathways that reflected more transcriptional
activity and enhanced T-cell responses and less co-stimulation in
responding patients, whereas non-responding patients had more
active immunosuppressive pathways. Our results confirm that
inhibitory pathways impact disease state and underscore the
importance of regulating these pathways while concomitantly
stimulating effector T cells for maximum clinical benefit.
Notably, in addition to up-regulation of genes associated with
lymphocyte activation pathways in responders, the CTLA4 gene
was less up-regulated in responders. We have previously shown
that the number of TREG cells induced by treatment correlates
with response in this cohort of patients and now we demonstrate
that the level of CTLA4 gene expression is altered and relates to
response as well. [36] CTLA4 manifold control of tolerance is
complex and involves competition with co-stimulatory molecules,
dysregulation of the immunological synapse, inhibition of inflam-
matory cytokines, and preservation of CD4+ TREG cell function.
[37] Therapies with anti-CTLA4 blocking antibodies have some
modest benefit in cancer patients. [38,39] Taken together with our
data, these studies suggest that suppressing CTLA4 signaling may
be necessary but not sufficient for robust clinical response in
cancer patients.
Gene expression of PBLs for responding patients also revealed
an up-regulation of the HIFa and Flt3 pathways, and cluster
analysis of genes in these pathways could discriminate NR from R
patients. Evidence has been provided that hypoxia may down-
regulate T-cell functions and an up-regulation of HIFa in
lymphocytes may contribute to more vigorous anti-tumor effect
at the hypoxic tumor microenvironment. [40] Flt3 is a tyrosine-
kinase receptor involved in the early stages of development of
hematopoietic cells. Flt3 is critical in the recovery of both B and T
cells following myeloablative therapy, and can promote myeloid
dendritic cell differentiation. [41–43] In contrast to its role in
hematopoietic malignancies, an increase in genes of the Flt3
pathway in responding patients suggests that the induction of
lymphopoiesis is an important step in stimulating anti-cancer
immune responses in solid tumors. Interestingly, other studies have
found that HIFa deficiency interferes with B and T cell function,
[44] while HIFa expression in immune cells promotes cell survival
and function. [45] These pathways may be useful biomarkers to
predict outcome if confirmed in larger prospective immunother-
apy studies.
Our goal of finding a predictive gene signature as a diagnostic
tool that correlates with clinical outcome may have been limited
by the small size of our study and the variation in the dataset due
to patient individuality. Even though multiple studies have shown
that expression profiling of the tumor itself can in principle be used
to develop classifiers that allow prediction of prognosis or
therapeutic responses, [46,47] it has been very difficult to translate
gene expression data into the clinic. [48,49] As have many others,
our study can distinguish between cancer patients and controls,
[8–10,50,51] but the use of expression profiling of PBL/PBMC of
patients as a surrogate biomarker in cancer will require much
more work e.g. gene signature monitoring under therapy in the
setting of much larger studies.
Nevertheless, we were able to observe differential regulation of
genes enriched in immune activation and regulatory pathways in
responding and non-responding patients upon immunotherapy.
This type of analysis remains promising for ultimately identifying
subpopulations of patients with unique potential to benefit from
specific targeted therapies. Knowing the disposition of each
patient’s immune system to activate regulatory or inflammatory
pathways upon immune therapy will select candidate patients for
e.g. a therapy with CTLA4-antagonist and IL2. Determining each
patient’s immune gene profile before therapy might guide the
decision for using immune therapy after a reasonable risk-benefit
assessment and therefore enhance therapeutic responses to
anticancer-immunotherapy by bolstering anti-tumor immune
responses.
Supporting Information
Figure S1 Supervised hierarchical clustering analysis
for T-cell and B-cell receptor associated genes of all
arrays was performed. Patients and healthy controls form
distinct clusters. This supports the finding of altered T- and B-cell
signaling and activation in mRCC patients.
(TIF)
Figure S2 Genes that were differentially regulated
between mRCC patients pre and post-treatment (based
on p,0.05, logFC .1,4) were selected for clustering
analysis that is displayed as a heatmap. (green means low
expression of a specific gene, red means high expression of a
specific gene) This supervised analysis shows no distinct grouping
of patient PBL gene signatures PRE and POST immunotherapy.
(TIF)
Figure S3 Supervised hierarchical clustering of re-
sponding versus non-responding patients (based on
p,0.05, logFC .1,4) is displayed as a heatmap for pre-
Figure 4. Comparison of treatment related changes in gene expression for responding versus non-responding patients (POST
minus PRE). Immune therapy leads to activation of stimulatory pathways in responding subjects. Examples of activated pathways are shown. The
CD28 co-stimulatory, nuclear factor of activated T-cell (NFAT) and HIFa pathways were relatively up-regulated (Figure 4A–4C) for responding subjects.
Another key pathway (IPA) differentially regulated in R vs. NR PBLs was the Flt3 signaling pathway (fms-like tyrosine kinase receptor-3; CD135) in
which genes were overall down-regulated in non-responding patients but up-regulated in responding patients (Figure 4D). To determine whether
the genes picked by ingenuity software are able to discriminate between responding and non-responding patients, we performed supervised
(selected genes) clustering analysis of genes important for Flt3 signaling. This clearly grouped responders and non-responders in 2 distinct groups
(Figure 4D), strengthening the IPA-result. Supervised clusters of pathways in 4A–4C led to similar results (data not shown).
doi:10.1371/journal.pone.0050221.g004
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treatment (3A) and post-treatment (3B) PBLs. No
distinct clustering of the two groups occurs.
(TIF)
Figure S4 Comparison of treatment related changes in
gene expression for responding versus non-responding
patients (POST minus PRE) and analysis with IPA.
Immune therapy leads to decreased expression of CTLA4 related
genes in responding subjects.
(TIF)
Figure S5 Peripheral blood serum concentrations for
the cytokine Interferon inducible factor 10, IP-10 for
healthy controls and mRCC patients PRE and POST
treatment as a group and split based on response (n: 5
healthy controls, 8 mRCC: 4 R PRE, 4 NR PRE, 4 R
POST, 4 NR POST). RCC patients show significantly higher
levels of IP-10. Responders have higher levels of IP10 PRE (ns,
p = 0.08). IP-10 serum levels increase with immune therapy in R
and NR. This increase is significant for the patient group (p,0.01)
and for the smaller group of responding patients (p,0.05).
(TIF)
Figure S6 Correlation between the Fold Changes of 132
RCC-associated transcripts identified in PBMCs by
Twine et al (1), and the corresponding fold change for
our PBL based data set. The analysis revealed no similarities
in gene expression levels which may be due to additional
monocyte derived cell types in the PBMCs.
(TIF)
Table S1 Primer assays for RT-PCR.
(DOCX)
Table S2 Validation of index genes with RT-PCR.
Differences in gene expression for patients vs. healthy
controls as well as PRE vs. POST seen in microarray
analysis could be confirmed with RT-PCR. Negative fold
changes in microarray analysis as seen on the right side for PRE
vs. POST correlate to corresponding RT-PCR fold changes. Two
methods of fold change calculation (difference vs. ratio) had to be
taken into account. Same RNA specimens were used for
microarray analysis and RT-PCR. A clear correlation between
relative expression values in RT-PCR with microarray analysis
could be shown for all tested genes.
(DOCX)
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